LLY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Eli Lilly (LLY) shows strong financial performance and positive growth catalysts, but the lack of immediate trading signals, insider selling activity, and cautious congressional trading suggest a 'hold' recommendation for a beginner investor with a long-term strategy. The stock is not currently at an optimal entry point.
The MACD is positive and expanding, indicating bullish momentum. However, RSI at 48.077 is neutral, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 921.337, with support at 889.696 and resistance at 952.978.
FDA approval of Foundayo positions Eli Lilly strongly in the obesity and metabolic franchise. Analysts have raised price targets, with the highest being $1,327, reflecting confidence in the company's growth potential. Financials show robust YoY growth in revenue, net income, and EPS.
Insider selling has surged by 4519.16% over the last month, and congressional trading data shows a recent sale transaction, indicating cautious sentiment. The stock's short-term trend suggests potential declines in the next week and month.
In Q4 2025, Eli Lilly reported a 42.56% YoY increase in revenue, a 50.52% YoY increase in net income, and a 51.43% YoY increase in EPS. Gross margin improved slightly to 82.52%. These figures highlight strong financial growth and operational efficiency.
Analysts maintain a positive outlook with multiple Buy and Overweight ratings. Price targets have been raised recently, with the highest at $1,327. The FDA approval of Foundayo and strong clinical trial results for retatrutide are key drivers of optimism.
